- Home
- PLSE vs VKTX Comparison
PLSE vs VKTX Comparison
Compare PLSE & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLSE | VKTX |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.0B |
| IPO Year | 2015 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PLSE | VKTX |
|---|---|---|
| Price | $52.89 | $25.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 21 |
| Target Price | $60.67 | ★ $94.50 |
| AVG Volume (30 Days) | 408.8K | ★ 6.8M |
| Earning Date | 11-04-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $480.71 | N/A |
| Revenue Next Year | $177.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.56 | $24.94 |
| 52 Week High | $58.90 | $43.15 |
Technical Indicators
Market Signals| Indicator | PLSE | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.39 | 39.23 |
| Support Level | $49.01 | N/A |
| Resistance Level | $55.36 | $35.57 |
| Average True Range (ATR) | 3.43 | 1.40 |
| MACD | 0.13 | -0.16 |
| Stochastic Oscillator | 84.76 | 16.13 |
Price Performance
Historical ComparisonAbout PLSE Pulse Biosciences Inc (DE)
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.